{
  "id": 1930372,
  "title": "Sight Sciences Announces FDA Label Expansion For TearCare Dry Eye Therapy",
  "url": "https://urgent.news/2026/08/19/sight-sciences-announces-fda-label-expansion-for-tearcare-dry-eye",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-19T11:50:50.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/sight-sciences-announces-fda-label-expansion-tearcare-dry-eye-therapy"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Sight Sciences, Inc. (SGHT), an eyecare technology company, on Wednesday said the U.S. Food and Drug Administration has expanded the indications for its TearCare System, making it the first treatment for meibomian gland dysfunction or MGD specifically cleared to impro",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}